V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330008579 | 330005384 | 1.61 | 53.2 | Curative (C) | 2013-08-02 | 2013-08-02 | Ifosfamide 3g/m2 5 day | N | null | 330019929 | PERTUZUMAB + TRASTUZUMAB |
| 330008581 | 330008933 | 1.55 | 89 | Curative (C) | 2013-10-09 | 2013-10-09 | EMA/CO | N | N | 330019979 | CAP |
| 330008582 | 330005388 | null | 19.5 | Neo-adjuvant (N) | 2017-09-16 | 2017-09-18 | Cisplatin+Doxorubicin+Etoposide 28d | N | N | 330020003 | CISPLATIN + GEMCITABINE |
| 330008583 | 330005388 | 1.7 | 67.2 | Palliative (P) | 2015-01-24 | 2015-01-24 | Cytarabine Low Dose | N | N | 330020003 | CISPLATIN + DOX + ETOPOSIDE |
| 330008585 | 330005389 | 1.71 | 93.2 | Neo-adjuvant (N) | 2015-01-25 | 2015-02-14 | KESTREL Trial | 2 | N | 330020014 | CYTARABINE INTRATHECAL |
| 330008586 | 330008936 | 1.55 | 69 | Curative (C) | 2017-07-28 | 2017-09-23 | CARBOPLATIN + CETUXIMAB + FU | N | N | 330020032 | CARBOPLATIN + LIPOSOMAL DOX |
| 330008587 | 330008936 | 1.8 | 48 | Palliative (P) | null | 2016-03-12 | Cytarabine Low Dose | N | null | 330020032 | LENALIDOMIDE |
| 330008588 | 330008937 | 1.69 | 83.4 | Neo-adjuvant (N) | 2015-07-07 | 2015-08-11 | CETUXIMAB + CISPLATIN + FU | Y | N | 330020045 | DHAP |
| 330008590 | 330013077 | 1.61 | 80.6 | Curative (C) | 2017-06-15 | 2017-06-26 | CAPECITABINE + CARBOPLATIN + Cetuximab | N | null | 330020060 | CISPLATIN + ETOPOSIDE + RT |
| 330008591 | 330013077 | 1.81 | 84.1 | Curative (C) | null | 2016-01-24 | Capecitabine (14 days)+Carboplatin | null | null | 330020060 | CARBOPLATIN + CETUXIMAB + FU |
| 330008592 | 330013077 | 1.61 | 90.1 | Curative (C) | 2017-06-16 | 2017-07-03 | Capecitabine + Streptozocin | N | N | 330020060 | CYCLOPHOSPHAMIDE + VINORELBINE |
| 330008593 | 330005391 | null | 62 | Curative (C) | 2014-11-26 | 2015-03-29 | Triple Intrathecal | N | N | 330020076 | AML19 TRIAL |
| 330008594 | 330005392 | 1.64 | null | Palliative (P) | null | 2013-06-09 | FLUOROURACIL | 02 | N | 330020079 | PONATINIB |
| 330008595 | 330005392 | 1.65 | 72 | Curative (C) | 2014-12-01 | 2015-02-15 | AML 18 TRIAL | N | N | 330020079 | MITOXANTRONE |
| 330008597 | 330005394 | 1.6 | 51.5 | Adjuvant (A) | 2013-11-26 | 2013-12-21 | Hydroxycarbamide | N | N | 330020121 | CASPS TRIAL |
| 330008598 | 330005397 | 1.7 | 40.6 | Palliative (P) | 2016-09-19 | 2016-12-06 | Alemtuzumab + Cyclophos TBI Allo | N | N | 330020131 | VINCRISTINE |
| 330008599 | 330005398 | 1.63 | null | Curative (C) | 2014-09-09 | 2014-09-22 | Ipilimumab | 02 | N | 330020131 | EDP + MITOTANE |
| 330008600 | 330005399 | null | 51 | Palliative (P) | 2016-11-15 | 2017-02-12 | Pazopanib | null | null | 330020134 | CARBO + THIOTEPA + TOPOTECAN |
| 330008601 | 330005401 | 1.65 | 16.4 | Adjuvant (A) | 2017-12-24 | 2017-12-24 | Cisplatin + Paclitaxel | N | N | 330020153 | CARBOPLATIN + DOXORUBICIN |
| 330008602 | 330008943 | 1.6 | 0 | Neo-adjuvant (N) | 2016-06-20 | 2016-06-24 | BEP 3 day | 02 | N | 330020158 | CLOFARABINE + CYTARABINE |
| 330008603 | 330005404 | 1.77 | 92.4 | Curative (C) | 2017-02-02 | 2017-02-03 | IPO | 02 | N | 330020165 | IMATINIB |
| 330008604 | 330005405 | 1.15 | 89.15 | Curative (C) | 2018-02-12 | 2018-02-17 | AML17 TRIAL | 02 | N | 330020176 | PONATINIB |
| 330008605 | 330008944 | 1.77 | 80.2 | Palliative (P) | 2014-09-12 | 2014-10-28 | Doxorubicin + Ifosfamide | 2 | N | 330020179 | CETUXIMAB + CISPLATIN + FLUOROURACIL |
| 330008606 | 330005407 | 1.64 | 77.95 | Neo-adjuvant (N) | 2015-02-27 | 2015-02-28 | IPO | 02 | N | 330020179 | DOXORUBICIN + IFOSFAMIDE |
| 330008607 | 330005407 | 0 | 96.1 | Curative (C) | 2014-03-20 | 2014-03-22 | RUXOLITINIB | N | N | 330020179 | MITOTANE |
| 330008609 | 330008947 | 1.61 | 10.4 | Curative (C) | 2015-08-18 | 2015-08-30 | DACTINOMYCIN | N | N | 330020208 | EP/EMA |
| 330008610 | 330005410 | 1.65 | 64.5 | Curative (C) | null | 2016-04-20 | DHAP | null | N | 330020208 | EMA |
| 330008611 | 330005410 | 1.58 | 90.6 | Curative (C) | 2018-01-10 | 2018-01-12 | PAC-E | N | N | 330020208 | IBRUTINIB |
| 330008612 | 330005411 | 1.8 | 88.6 | Curative (C) | 2014-09-24 | 2014-10-09 | AML17 TRIAL | N | null | 330020223 | CAPECITABINE + CETUXIMAB + IRINOTECAN |
| 330008614 | 330010852 | 0 | 86.4 | Disease modification (D) | 2015-07-18 | 2016-03-15 | CVP R | Y | N | 330020231 | CAPECITABINE + CARBOPLATIN |
| 330008615 | 330011907 | 1.64 | null | Curative (C) | 2015-09-28 | 2015-10-03 | CARBOPLATIN + DOCETAXEL + FLUOROURACIL | 02 | null | 330020236 | CLOFARABINE + CYTARABINE |
| 330008616 | 330011907 | 1.32 | 65.8 | Adjuvant (A) | 2015-04-29 | 2015-05-09 | Vinorelbine (oral) | N | N | 330020236 | FCR |
| 330008618 | 330005417 | 1.82 | 91.6 | Curative (C) | 2013-07-15 | 2013-07-16 | Capecitabine + Cisplatin | N | N | 330020260 | BENDAMUSTINE |
| 330008619 | 330005418 | 1.58 | null | Neo-adjuvant (N) | null | 2017-04-11 | FIGARO TRIAL | 2 | N | 330020262 | CISPLATIN + ETOPOSIDE + PACLITAXEL |
| 330008620 | 330005419 | 1.76 | null | Disease modification (D) | 2013-11-13 | 2013-11-13 | STS Rhabdo RMS 2005 Vin Cyclo | N | N | 330020277 | CAPECITABINE + CARBOPLATIN |
| 330008621 | 330008953 | 1.83 | 69.6 | Palliative (P) | 2015-03-15 | 2015-03-21 | Vemurafenib | N | null | 330020277 | CETUXIMAB + CISPLATIN + FLUOROURACIL |
| 330008622 | 330011908 | 1.76 | 73.8 | Curative (C) | 2014-03-02 | 2014-03-04 | BEP 5 Day | Y | N | 330020280 | ETOPOSIDE + RITUXIMAB |
| 330008623 | 330005420 | null | null | Curative (C) | 2013-06-07 | 2013-06-17 | FCR Oral - Cycle 2 onwards | null | null | 330020280 | CHOP |
| 330008624 | 330005421 | 1.65 | 72.2 | Neo-adjuvant (N) | 2015-04-10 | 2015-04-18 | CYCLO + DOXORUBICIN + VINCRISTINE | N | N | 330020297 | ADE |
| 330008625 | 330005421 | 1.83 | 67.6 | Curative (C) | 2018-02-03 | 2018-03-31 | BLINATUMOMAB | null | N | 330020297 | VINCRISTINE |
| 330008626 | 330011909 | 1.76 | 84.5 | Curative (C) | 2016-03-31 | 2016-06-26 | CYCLO + DOXORUBICIN + VINCRISTINE | 02 | N | 330020306 | THALIDOMIDE |
| 330008627 | 330005424 | null | 93 | null | 2016-02-29 | 2016-03-01 | CNS LGG 2004 03 vinc weekly+ carbo | N | N | 330020321 | CAP |
| 330008628 | 330008958 | 1.8 | 52.3 | Adjuvant (A) | 2014-08-28 | 2014-09-10 | VINCRISTINE | N | N | 330020323 | CYTARABINE |
| 330008629 | 330010856 | 1.63 | 83.2 | Curative (C) | 2014-08-10 | 2014-08-19 | Cyclophosphamide High Dose | Y | N | 330020332 | DOXORUBICIN + OLARATUMAB |
| 330008630 | 330005426 | 1.63 | 84 | Curative (C) | 2013-09-02 | 2013-12-20 | Bendamustine +/- Prednisolone | N | N | 330020341 | CISPLATIN + GEMCITABINE |
| 330008631 | 330005426 | 1.68 | 65 | Curative (C) | 2016-12-10 | 2016-12-25 | Hydroxycarbamide | N | null | 330020341 | EC |
| 330008632 | 330008960 | 0 | 98.2 | Adjuvant (A) | 2018-03-10 | 2018-04-14 | STS Rhabdomyosarcoma RMS 2005 IVA | null | N | 330020348 | BORTEZOMIB |
| 330008633 | 330005428 | null | 59.7 | Neo-adjuvant (N) | 2015-07-05 | 2015-08-14 | CVP R | N | null | 330020376 | CISPLATIN + GEMCITABINE |
| 330008634 | 330005428 | 1.65 | 70 | Curative (C) | 2017-06-15 | 2017-06-16 | Dactinomycin + Vincristine | 02 | N | 330020376 | CHLORAMBUCIL + RITUXIMAB |
| 330008635 | 330011910 | 1.67 | 101 | Palliative (P) | 2014-09-10 | 2014-09-13 | Doxorubicin + Olaratumab | 2 | N | 330020388 | EMA |